Literature DB >> 30447932

Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical Center.

Samuel J Galgano1, Carli E Calderone2, Andrew M McDonald3, Jeffrey W Nix4, Mollie deShazo5, Eddy S Yang3, Jonathan E McConathy2, Soroush Rais-Bahrami6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30447932      PMCID： PMC8983102          DOI： 10.1016/j.jacr.2018.09.026

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN： 1546-1440            Impact factor:   5.532


× No keyword cloud information.
  10 in total

1.  Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy.

Authors:  Luca F Valle; Matthew D Greer; Joanna H Shih; Tristan Barrett; Yan Mee Law; Andrew B Rosenkrantz; Haytham Shebel; Akhil Muthigi; Daniel Su; Maria J Merino; Bradford J Wood; Peter A Pinto; Andra V Krauze; Aradhana Kaushal; Peter L Choyke; Barış Türkbey; Deborah E Citrin
Journal:  Diagn Interv Radiol       Date:  2018 Jan-Feb       Impact factor: 2.630

2.  Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.

Authors:  Win Shun Lai; Jennifer B Gordetsky; John V Thomas; Jeffrey W Nix; Soroush Rais-Bahrami
Journal:  Cancer       Date:  2017-01-31       Impact factor: 6.860

3.  Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate pancer: multicenter Phase IIb clinical trial.

Authors:  Hiroyoshi Suzuki; Yusuke Inoue; Hiroyuki Fujimoto; Junji Yonese; Kazunari Tanabe; Satoshi Fukasawa; Tomio Inoue; Shiro Saito; Munehisa Ueno; Akiharu Otaka
Journal:  Jpn J Clin Oncol       Date:  2017-03-01       Impact factor: 3.019

4.  (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

Authors:  Cristina Nanni; Lucia Zanoni; Cristian Pultrone; Riccardo Schiavina; Eugenio Brunocilla; Filippo Lodi; Claudio Malizia; Matteo Ferrari; Patrizio Rigatti; Cristina Fonti; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-10       Impact factor: 9.236

Review 5.  Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer.

Authors:  Pritesh Patel; Melvy S Mathew; Igor Trilisky; Aytekin Oto
Journal:  Radiographics       Date:  2018-01-26       Impact factor: 5.333

6.  Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.

Authors:  Berrend G Muller; Aradhana Kaushal; Sandeep Sankineni; Elena Lita; Anthony N Hoang; Arvin K George; Soroush Rais-Bahrami; Jochen Kruecker; Pingkun Yan; Sheng Xu; Jean J de la Rosette; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Urol Oncol       Date:  2015-08-08       Impact factor: 3.498

7.  Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Authors:  Oluwaseun A Odewole; Funmilayo I Tade; Peter T Nieh; Bital Savir-Baruch; Ashesh B Jani; Viraj A Master; Peter J Rossi; Raghuveer K Halkar; Adeboye O Osunkoya; Oladunni Akin-Akintayo; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-18       Impact factor: 9.236

8.  Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

Authors:  David M Schuster; Peter T Nieh; Ashesh B Jani; Rianot Amzat; F Dubois Bowman; Raghuveer K Halkar; Viraj A Master; Jonathon A Nye; Oluwaseun A Odewole; Adeboye O Osunkoya; Bital Savir-Baruch; Pooneh Alaei-Taleghani; Mark M Goodman
Journal:  J Urol       Date:  2013-10-19       Impact factor: 7.450

9.  Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose.

Authors:  Shuntaro Oka; Hiroyuki Okudaira; Masahiro Ono; David M Schuster; Mark M Goodman; Keiichi Kawai; Yoshifumi Shirakami
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

10.  L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.

Authors:  Atsuki Segawa; Shushi Nagamori; Yoshikatsu Kanai; Nobuhide Masawa; Tetsunari Oyama
Journal:  Mol Clin Oncol       Date:  2012-12-20
  10 in total
  2 in total

1.  [18F]Fluciclovine-PET Guided Salvage Lymph Node Dissection Following Radical Prostatectomy.

Authors:  Samuel J Galgano; Carli E Calderone; Jeffrey W Nix; Soroush Rais-Bahrami
Journal:  Urology       Date:  2019-05-29       Impact factor: 2.649

2.  Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.

Authors:  Hala T Borno; Tracy Kuo Lin; Anobel Y Odisho; Arpita Desai; Vadim Koshkin; Kalin Werner; Nichole Legaspi; Matthew Bucknor; Alexander Bell; Sylvia Zhang; Thomas A Hope
Journal:  Cancer Med       Date:  2020-11-28       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.